Reuters -- Bristol-Myers Squibb Co on Tuesday said its first-quarter profit slipped 3 percent, as negative foreign exchange factors and falling sales of its Erbitux cancer medicine more than offset higher revenue from other medicines.
Reuters -- Bristol-Myers Squibb Co on Tuesday said its first-quarter profit slipped 3 percent, as negative foreign exchange factors and falling sales of its Erbitux cancer medicine more than offset higher revenue from other medicines.
